55P - CTC count & gene expression profiling among Filipino NSCLC

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Thoracic malignancies
Translational Research
Presenter Herdee Gloriane Luna
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors H.G. Luna, G. Cristal-Luna
  • Internal Medicine, Section Of Medical Oncology, National Kidney and Transplant Institute, 1102 - Quezon City/PH

Abstract

Background

CTC count with gene expression profiling’s prognostic value has been documented in mBRCA, mPC & mCRC. Presently, there is a challenge in understanding its prognostic value among Filipino NSCLC patients. This study aims to describe first data on Filipino NSCLC CTC count & gene expression profile.

Methods

Charts of mNSCLC patients who underwent procedure from Jan 2014 to Jan 2016 were reviewed. CTC count was done using EpCam-targeted magnetic beads on blood extracts then immunofluorescence of cell surface markers (DAPI+ CD45- CK+). Gene expression profiling through RT PCR of buffy coat RNA extracts was done using 3 tumor asso-genes (CD133 CK19 MUC1). Demographics, histo, EGFR mutation, available CTC count & gene expression profiling, treatment, objective response after 3 treatment cycles & TTP were described.

Results

12 NSCLC were analyzed. 66% were male, 62+/- 10 years. 75% Adeno & 25% Sq. 50% EGFR MT, 42% EGFR WT, 8% unknown EGFR status. Baseline CTC count ranged from 0-3 (mean:0.91). Post tx CTC count ranged 0-2 (mean: 0.66) in 6 subjects. 12 subjects with baseline gene expressions showed CD133 upregulated in 50%, KRT19 upregulated in 33% & MUC1 upregulated in 66%. EGFR MT adeno (n = 5) received chemo followed by TKI in 60% (CR 33% PR 33% PD 33% TTP 66% NR) & TKI only in 40% (CR 50% SD 50% TTP 50% NR). EGFR MT Sq (n = 1) received chemo (CR 100% TTP NR). Among EGFR WT (Ad n = 3, Sq = 2), all received chemo (PR 60% SD 20% PD 20% TTP 80% NR). 100% of unknown EGFR received chemo was in CR. 2/3 with post tx gene expression showed 44% change in expression, n = 4/9.rn

Table: 55P NSCLC CTC count & gene expression pre & post tx

rnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrn
rnBaselinePost Txrn
HistoEGFRCTCCD133KRT19MUC1CTCCD133KRT19MUC1TxORTTP
AMT0UNU2UNUCTCRNR
SMT0NND0UNNCCRNR
AWT1UNU1NNNCSDNR
rn

A-Adeno S-Sq U-upregulated N-negative D-downregulated NR-not reached

rn

Conclusions

NSCLC is an aggressive disease despite Filipino CTC count ranging from 0-3. However, upregulation in at least one baseline gene among subjects was noted in 75% of cases, while 41% showed upregulation in 2 baseline genes (CD133 and MUC1). Post treatment gene expression were changed in 44%. Additional research is needed to gain insight on significance of change in gene expressions in order to provide information on treatment & outcomes.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.